| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2143020 | Lung Cancer | 2009 | 5 Pages |
Abstract
The combination of UFT, etoposide and leucovorin is active in 2nd or 3rd line therapy of Caucasian NSCLC patients and because of its favourable toxicity profile this treatment warrants further investigation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
V. Surmont, J.G. Aerts, E. Pouw, K.Y. Tan, R. Vernhout, J. Gras, J. Salomé, T. Pronk, P.I.M. Schmitz, H. Hoogsteden, R.J. van Klaveren,